NEW YORK, July 1 /PRNewswire-Asia-FirstCall/ —
NeoStem, Inc. (NYSE Amex: NBS) (“NeoStem” or the “Company”), an
international biopharmaceutical company with operations in the U.S.
and China, today announced that it
has appointed Roberto Bolli, M.D.,
to its Scientific Advisory Board. Dr. Bolli has produced an immense
body of stem-cell research, including work emphasizing the ability
of very small embryonic-like stem cells (VSELs) to regenerate and
repair after myocardial infarction. He has received numerous awards
and honors, produced over 300 peer-reviewed publications and
lectured various audiences on topics related to his cardiovascular
research, which has spanned three decades.
Dr. Bolli currently serves as Chief of the Division of
Cardiology at the University of
Louisville and is Director at the school’s Institute of
Molecular Cardiology. He also has been named Executive Vice
Chairman of University of Louisville’s
Department of Medicine. He holds the Jewish Hospital Distinguished
Chair in Cardiology and has pioneered, developed and led research
programs from the ground up at both Baylor
University and the University of
Louisville.
Wayne A. Marasco, M.D., Ph.D.,
chair of NeoStem’s Scientific Advisory Board, said, “We are
extremely pleased to have Dr. Bolli join our advisory team. His
in-depth understanding of the intricacies of VSELs and their
potential to regenerate damaged heart tissue compliments well our
goal of commercializing VSEL(TM) technology to improve the
‘/>”/>
SOURCE
